Question 3What is the current “standard care” in the UK for people with MND?

GDG1Pharmacological therapy (Riluzole and other symptomatic drug therapy); routine monitoring of respiratory muscle function; techniques to assist cough and deal with problems with saliva; nutritional support (including gastrostomy); physical aids to improve mobility and communications; palliative care including end of life care
GDG2Riluzole; gastrostomy (PEG/RIG); nutritional support; physiotherapy; OT; SLT; palliative care including end of life care
GDG3Riluzole; NIV; palliative care
GDG4NIV; opioids
GDG7NIV; support for dysphagia & nutrition; end of life care; secretion management; emotional support; maximising physical function; supporting carers; improve communication; spasticity management
GDG8Riluzole; palliative care; physiotherapy; OT; SLT; nutritional support (including gastrastomy); NIV
GDG11Riluzole and respiratory support
GDG12Vary widely
GDG13Vary widely

From: Appendix 9.3, Results of GDG short questionnaires

Cover of Motor Neurone Disease
Motor Neurone Disease: The Use of Non-Invasive Ventilation in the Management of Motor Neurone Disease [Internet].
NICE Clinical Guidelines, No. 105.
Centre for Clinical Practice at NICE (UK).
Copyright © 2010, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.